Cargando…

Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a comprehensive update

BACKGROUND: Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, also referred to as Müllerian aplasia, is a congenital disorder characterized by aplasia of the uterus and upper part of the vagina in females with normal secondary sex characteristics and a normal female karyotype (46,XX). MAIN BODY: The d...

Descripción completa

Detalles Bibliográficos
Autores principales: Herlin, Morten Krogh, Petersen, Michael Bjørn, Brännström, Mats
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439721/
https://www.ncbi.nlm.nih.gov/pubmed/32819397
http://dx.doi.org/10.1186/s13023-020-01491-9
_version_ 1783573037431390208
author Herlin, Morten Krogh
Petersen, Michael Bjørn
Brännström, Mats
author_facet Herlin, Morten Krogh
Petersen, Michael Bjørn
Brännström, Mats
author_sort Herlin, Morten Krogh
collection PubMed
description BACKGROUND: Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, also referred to as Müllerian aplasia, is a congenital disorder characterized by aplasia of the uterus and upper part of the vagina in females with normal secondary sex characteristics and a normal female karyotype (46,XX). MAIN BODY: The diagnosis is often made during adolescence following investigations for primary amenorrhea and has an estimated prevalence of 1 in 5000 live female births. MRKH syndrome is classified as type I (isolated uterovaginal aplasia) or type II (associated with extragenital manifestations). Extragenital anomalies typically include renal, skeletal, ear, or cardiac malformations. The etiology of MRKH syndrome still remains elusive, however increasing reports of familial clustering point towards genetic causes and the use of various genomic techniques has allowed the identification of promising recurrent genetic abnormalities in some patients. The psychosexual impact of having MRKH syndrome should not be underestimated and the clinical care foremost involves thorough counselling and support in careful dialogue with the patient. Vaginal agenesis therapy is available for mature patients following therapeutical counselling and education with non-invasive vaginal dilations recommended as first-line therapy or by surgery. MRKH syndrome involves absolute uterine factor infertility and until recently, the only option for the patients to achieve biological motherhood was through gestational surrogacy, which is prohibited in most countries. However, the successful clinical trial of uterus transplantation (UTx) by a Swedish team followed by the first live-birth in September, 2014 in Gothenburg, proofed the first available fertility treatment in MRKH syndrome and UTx is now being performed in other countries around the world allowing women with MRKH syndrome to carry their own child and achieve biological motherhood. CONCLUSION: Several advances in research across multiple disciplines have been made in the recent years and this kaleidoscopic review provides a current status of various key aspects in MRKH syndrome and provides perspectives for future research and improved clinical care.
format Online
Article
Text
id pubmed-7439721
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74397212020-08-24 Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a comprehensive update Herlin, Morten Krogh Petersen, Michael Bjørn Brännström, Mats Orphanet J Rare Dis Review BACKGROUND: Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome, also referred to as Müllerian aplasia, is a congenital disorder characterized by aplasia of the uterus and upper part of the vagina in females with normal secondary sex characteristics and a normal female karyotype (46,XX). MAIN BODY: The diagnosis is often made during adolescence following investigations for primary amenorrhea and has an estimated prevalence of 1 in 5000 live female births. MRKH syndrome is classified as type I (isolated uterovaginal aplasia) or type II (associated with extragenital manifestations). Extragenital anomalies typically include renal, skeletal, ear, or cardiac malformations. The etiology of MRKH syndrome still remains elusive, however increasing reports of familial clustering point towards genetic causes and the use of various genomic techniques has allowed the identification of promising recurrent genetic abnormalities in some patients. The psychosexual impact of having MRKH syndrome should not be underestimated and the clinical care foremost involves thorough counselling and support in careful dialogue with the patient. Vaginal agenesis therapy is available for mature patients following therapeutical counselling and education with non-invasive vaginal dilations recommended as first-line therapy or by surgery. MRKH syndrome involves absolute uterine factor infertility and until recently, the only option for the patients to achieve biological motherhood was through gestational surrogacy, which is prohibited in most countries. However, the successful clinical trial of uterus transplantation (UTx) by a Swedish team followed by the first live-birth in September, 2014 in Gothenburg, proofed the first available fertility treatment in MRKH syndrome and UTx is now being performed in other countries around the world allowing women with MRKH syndrome to carry their own child and achieve biological motherhood. CONCLUSION: Several advances in research across multiple disciplines have been made in the recent years and this kaleidoscopic review provides a current status of various key aspects in MRKH syndrome and provides perspectives for future research and improved clinical care. BioMed Central 2020-08-20 /pmc/articles/PMC7439721/ /pubmed/32819397 http://dx.doi.org/10.1186/s13023-020-01491-9 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
Herlin, Morten Krogh
Petersen, Michael Bjørn
Brännström, Mats
Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a comprehensive update
title Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a comprehensive update
title_full Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a comprehensive update
title_fullStr Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a comprehensive update
title_full_unstemmed Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a comprehensive update
title_short Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome: a comprehensive update
title_sort mayer-rokitansky-küster-hauser (mrkh) syndrome: a comprehensive update
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7439721/
https://www.ncbi.nlm.nih.gov/pubmed/32819397
http://dx.doi.org/10.1186/s13023-020-01491-9
work_keys_str_mv AT herlinmortenkrogh mayerrokitanskykusterhausermrkhsyndromeacomprehensiveupdate
AT petersenmichaelbjørn mayerrokitanskykusterhausermrkhsyndromeacomprehensiveupdate
AT brannstrommats mayerrokitanskykusterhausermrkhsyndromeacomprehensiveupdate